Woodland Park, January 27, 2016 ---Cytec, a member of the Solvay Group is demonstrating how its pharmaceutical grade surfactants can provide solutions for the “solubility challenges” in the pharmaceutical industry. The business is showcasing its existing docusate sodium products and launching its new DocuSolv™ pharmaceutical grade surfactants at the 5th Annual Drug Formulation and Bioavailability Summit in Philadelphia from January 25 to 27, 2016.The docusate sodium products are pharmaceutical grade surfactants, manufactured under current Goods Manufactured Products (cGMP) and US Food and Drugs Administration (FDA) conditions, meeting United States, European and Japanese pharmacopeias. These products are already used as excipients in a large number of oral solid dose formulation (OSDF) products that have been in the market for a number of years and similarly in other product forms. Cytec Solvay Group is the holder of the docusate sodium drug master file that the FDA has recently re-classified as Type IV.The new DocuSolv™ pharmaceutical grade surfactants are specifically formulated for use as excipients in OSDF. They exhibit all the characteristics of docusate while offering additional handling and faster dissolution. These unique formulation aids offer:
- Smaller particle size that dissolves faster and expands formulation effectiveness of more APIs
- Better handling and reduction in processing time
- Enriched bioavailability via decreased dissolution times under stomach conditions
- Enhanced solubility, dispersion and wettability of API
- Easy to create solutions with higher concentrations
Cytec Solvay Group is the leading manufacturer and supplier of this chemistry to the pharmaceutical market. To register to receive a copy of a technical brochure that discusses the benefits of docusate sodium use as an industry-leading pharmaceutical grade surfactant, visit
https://www.cytec.com/businesses/additive-technologies/specialty-additives/docusate-sodium. To learn more about DocuSolv™ pharmaceutical grade surfactants at the Drug Formulation and Bioavailability Summit, show attendees can visit our representatives in the main exhibition area or visit
www.cytec.com/sa/pharma.Disclaimer: Cytec Industries Inc. in its own name and on behalf of its affiliated companies (collectively, “Cytec”) decline any liability with respect to the use made by anyone of the information contained herein. The information contained herein represents Cytec’s best knowledge thereon without constituting any express or implied guarantee or warranty of any kind (including, but not limited to, regarding the accuracy, the completeness or relevance of the data set out herein).Nothing contained herein shall be construed as conferring any license or right under any patent or other intellectual property rights of Cytec or of any third party. The information relating to the products is given for information purposes only. No guarantee or warranty is provided that the product and/or information is adapted for any specific use, performance or result and that product and/or information do not infringe any Cytec and/or third party intellectual property rights.The user should perform its own tests to determine the suitability for a particular purpose. The final choice of use of a product and/or information as well as the investigation of any possible violation of intellectual property rights of Cytec and/or third parties remains the sole responsibility of the user.TRADEMARK NOTICE: The ® indicates a Registered Trademark in the United States and the ™ indicates a trademark in the United States. The mark may also be registered, subject of an application for registration, or a trademark in other countries.All trademarks are the property of their respective owners.Media Contacts
Tara Tepp
In Process Separation Marketing Communications
Tel: 1.973.357.3347
tara.tepp@cytec.com
Katherine Vaiente
Global Marketing Communications Manager
Tel: 1.480.730.2310
Katherine.Vaiente@cytec.com
